Drug Profile
CRB 0022
Alternative Names: CRB-0022Latest Information Update: 25 Sep 2019
Price :
$50
*
At a glance
- Originator Rottapharm Madaus
- Developer Rottapharm Biotech
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 19 Sep 2019 Discontinued for Pain in Italy (Parenteral) Rottapharm Biotech pipeline September 2019
- 01 Nov 2014 Research and exploratory development is ongoing in Italy
- 10 Oct 2014 Rottapharm Madaus has been acquired by Meda